Quarterly ResultApr 27, 2026, 07:11 AM
FULC Q1 Results; Pociredir Positive Data; Cash Runway into 2029
AI Summary
Fulcrum Therapeutics reported Q1 2026 financial results, ending the quarter with $333.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029. The company presented positive clinical data for pociredir in sickle cell disease, showing robust fetal hemoglobin induction and improvements in hemolysis and anemia markers, with plans to initiate a potential registration-enabling trial in H2 2026. Additionally, Fulcrum terminated its license agreement with CAMP4 Therapeutics for the Diamond-Blackfan anemia program and announced the retirement of CFO Alan Musso later this year, while appointing Josh Lehrer to the Board of Directors.
Key Highlights
- Presented positive clinical data for pociredir in SCD, showing robust HbF induction.
- Plans to initiate a potential registration-enabling trial for pociredir in H2 2026.
- Ended Q1 2026 with $333.3 million in cash, cash equivalents, and marketable securities.
- Cash runway expected to fund operations into 2029.
- Q1 2026 net loss was $18.9 million, compared to $17.7 million in Q1 2025.
- Terminated License Agreement with CAMP4 Therapeutics for Diamond-Blackfan anemia program.
- CFO Alan Musso to retire; Josh Lehrer appointed to Board of Directors.